With a market cap of $10 billion, Revvity, Inc. (RVTY) is a global provider of health sciences solutions, technologies, and services. The company delivers a broad portfolio that includes instruments, reagents, informatics, software, imaging technologies, DNA sequencing services, and diagnostic platforms for genetic and infectious disease testing.
Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Revvity fits this criterion perfectly. Serving pharmaceutical and biotechnology companies, research institutions, healthcare providers, and government agencies, Revvity supports advancements in diagnostics, drug discovery, genomics, and public health.
Shares of the Waltham, Massachusetts-based company have fallen 33.1% from its 52-week high of $129.50. Revvity’s shares have declined 8.8% over the past three months, lagging behind the Health Care Select Sector SPDR Fund’s (XLV) 3.7% gain over the same time frame.
Longer term, RVTY stock is down 22.4% on a YTD basis, underperforming XLV’s marginal drop. Moreover, shares of the company have decreased 29.1% over the past 52 weeks, compared to XLV’s 11.2% dip over the same time frame.
Despite a few fluctuations, the stock has been trading below its 50-day and 200-day moving averages since February.
Shares of Revvity tumbled 8.3% on Jul. 28 after the company cut its full-year adjusted profit forecast to $4.85 per share – $4.95 per share, citing weaker demand in China. Sales of diagnostic products in China declined by double digits in Q2 2025 as new reimbursement policies tied to Diagnosis-Related Groups (DRGs) drove hospitals to shift from Revvity’s higher-value multiplex tests to lower-priced single-plex alternatives.
As a result, the company expects diagnostics sales to grow only in the low single digits versus its earlier mid-single digit forecast.
In contrast, rival IQVIA Holdings Inc. (IQV) has shown a less pronounced decline than RVTY stock. IQV stock has dipped 4.1% on a YTD basis and 21.7% over the past 52 weeks.
Despite RVTY’s weak performance, analysts remain moderately optimistic about its prospects. The stock has a consensus rating of “Moderate Buy” from 18 analysts in coverage, and the mean price target of $114.62 is a premium of 33.7% to current levels.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com